Ocular Therapeutix, INC 10-Q quarterly reports

Ocular Therapeutix reports progress in its AXPAXLI clinical trials for wet AMD and diabetic retinopathy, alongside Q2 2026 financial results showing increased R&D spending and continued net losses.

Ocular Therapeutix reports positive Q1 2026 results, driven by strong clinical trial data for AXPAXLI and modest growth in DEXTENZA revenue, while managing increased R&D expenses.

Ocular Therapeutix reports Q3 2025 financial results, highlighting a significant capital raise and continued progress in its late-stage retinal disease clinical programs for AXPAXLI.

Ocular Therapeutix, Inc. reported increased net losses and decreased product revenue in Q2 2025, driven by significant R&D investments in its late-stage retinal disease programs, while extending its cash runway into 2028.

Ocular Therapeutix announces its Q1 2025 financial results, focusing on the advancement of its AXPAXLI clinical trials and the commercial performance of DEXTENZA.

Ocular Therapeutix's Q3 2024 report shows a slight increase in product revenue and significant advancements in clinical trials for their key product candidates.

Ocular Therapeutix reports a net loss of $43.8 million for Q2 2024, while progressing its AXPAXLI clinical trials for wet AMD and seeing a 9% increase in DEXTENZA product revenue.

Ocular Therapeutix's first quarter of 2024 saw increased revenue and significant financial activity, including a substantial private placement and the conversion of convertible notes, alongside continued clinical trial advancements.